Enfrentando a Resistência Antifúngica

Cápsula de vídeo informativo sobre diversas abordagens para enfrentar o problema emergente da resistência antifúngica. Para assistir a este e outros vídeos de temas relacionados à infectologia, acesse nossa plataforma no link: https://www.pfizerpro.com/

PP-PFE-BRA-2776   

Referências:
- Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. Virulence. 2017;8(6):658–672.
- Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care.  Clin Infect Dis. 2013;56(9):1284-92.
- Ahmed A, Azim A, Baronia AK, et al. Risk prediction for invasive candidiasis.  Indian J Crit Care Med. 2014; 18(10): 682–688.
- Natesan SK. Evolution of Candida Diagnostics: Are We There Yet? J Mycol Mycological Sci 2019, 2(1): 000104.
- Pemán J, Zaragoza R. Hacia el diagnóstico temprano de la candidiasis invasora en el paciente crítico. Rev Iberoam Micol. 2012;29(2):71-75.
- Ben-Ami R. Treatment of Invasive Candidiasis: A Narrative Review.  J Fungi (Basel). 2018;4(3). pii: E97. 
- Garey KW, Rege M, Pai MP, et al.Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.  Clin Infect Dis. 2006;43(1):25-31. 
- Bassetti M, Righi E, Montravers P, Cornely OA.What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.  J Antimicrob Chemother. 2018;73(suppl_1):i14-i25.